Illustrations in Ulcerative Colitis

Slides:

Advertisements

Similar presentations

Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to.

Advertisements

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Cure’s GTX Licensing Opportunity

Miguel Regueiro, M.D. Professor of Medicine

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.

Progress in Diagnosing and Treating Clostridium difficile in IBD patients Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine Director of.

Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.

Therapeutic algorithms for Crohn’s disease: Where are we in 2012?

Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.

Controversies and challenges in the clinical care of patients with IBD: You can’t always get what you want! Stephen B. Hanauer, MD University of Chicago.

Ulcerative colitis.

Fecal calprotectin DR Amin Eftekhari.

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

Should we change how we position biologics in ulcerative colitis? Bruce E. Sands, MD, MS Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis R2 이 홍 주 Am J Gastroenterol 2009 ; 104 : 673 ~ 678.

Xavier Roblin, MD, PhD 1, M. Rinaudo, MD 2, E. Del Tedesco, MD 1, J.M. Phelip, MD, PhD 1, C. Genin, MD, PhD 2, L. Peyrin-Biroulet, MD, PhD 3 and S. Paul,

Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.

R3. 최태웅 / Pf. 김효종 Alimentary Pharmacology & Therapeutics 19 FEB 2016 DOI: /apt.13547

N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.

Cumulative Probability of Developing Colon Cancer in UC Patients

P0866 Combination of Low dose Thiopurine and Allopurinol in patients with ulcerative colitis Please export the Keynote document as a PDF (File – Save as.

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Issue Highlights Clinical Gastroenterology and Hepatology

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Changing the IBD Paradigm

Complicated Cases in Ulcerative Colitis

A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.

Challenges in Managing Progressive Multiple Sclerosis

Pathways in Managing Ulcerative Colitis

Disease Activity Assessment Across the RA Continuum

The future of urate-lowering strategies for gout

Laura Rosenberg, Kavinderjit S

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Antithrombotic Protection in CAD and HF

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Managing Adverse Events With New Oral Therapies in CLL

Raymond Cross, MD, MS, AGAF Associate Professor of Medicine

Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis? Hans H. Herfarth, MD, PhD Clinical.

Long-term outcome after infliximab for refractory ulcerative colitis

Mutational Testing to Select Novel Targeted Therapies in AML

Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab Dan Turner, Anne M. Griffiths,

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis M. De Vos, O. Dewit, G. D'Haens,

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Advancing the Treatment of IBD With Biologics

Article by: Zubin Grover , Richard Muir, and Peter lewindon

The emerging role of histologic disease activity assessment in ulcerative colitis Rish K. Pai, MD, PhD, Vipul Jairath, MD, PhD, Niels Vande Casteele,

Program Goals Overview Is NEDA a Reasonable Target?

Optimizing Outcomes in Crohn Disease

Methotrexate for Ulcerative Colitis: To Use or Not to Use?

Application of Biologics in IBD:

Volume 149, Issue 7, Pages e2 (December 2015)

Volume 148, Issue 5, Pages (May 2015)

Program Goals Overview Is NEDA a Reasonable Target?

Pathogenesis of IBD, and the Role of Biologic Therapies

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year.

Walter Reinisch, Jean-Frederic Colombel, William J

David S. Fefferman, Richard J. Farrell

Presentation data from US VICTORY Consortium

Comparative Studies of Biologics in Ulcerative Colitis

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

Patient Heterogeneity in CD

Presentation transcript:

Illustrations in Ulcerative Colitis

UC Endoscopic Spectrum of Severity

Histologic Architectural Distortion

CRP Levels and Endoscopic UC Severity

Fecal Calprotectin Predicts Endoscopically Active UC

Corticosteroids Dependency: Short- and Long-term Efficacy

Does Mucosal Healing Matter?

Goal of Therapy Mucosal Healing

UC SUCCESS Combination Azathioprine and Infliximab for UC Remission at Week 16

Fecal Calprotectin and Risk for Relapse

Feasibility of Treat to Target Mucosal and Histologic Healing in Practice

Surveillance for Dysplasia

Summary

Abbreviations

References

References (cont)

References (cont)